August 30, 1989 08:23

TO: GENNERY BRIAN A IVM1
LAMIE E WALTER IVM1
MAYR GERHARD IVM1
SCHULZE-SOLCE HANS MIKOLAUS IVM1
TAUREL SIDMEY IVM1
WEINSTEIN ALLAN J IVM1

CONFIDENTIAL

Rm: Additional Feedback Regarding the Fluoretine Review by the Commission A

Through additional contacts I have been able to find out the following. information:

- Only the 20 mg pack will be registered and the 50 mg, 40 mg and 60 mg packs will be denied registration on the ground that we have demonstrated the 20 mg is the right dose.
- The proposal of the Commission A for the indication would be: for the treatment of depressive illness when no sedation is necessary. This is very very close to the English package insert.
- 3. The counterindication because of acute suicidality should become a warning whereby the physicians should be advised that in the absence of sedation, the risk of higher suicidality should be taken intoaccount.
- 4. The counterindication for agitated patients and for patients with pronounced sleep disturbances should not be an absolute counter indication but rather a relative counterindication (this in Sermany is very similar to a precaution) whereby physicians would be particularly careful with those patients. An exact wording has not been proposed by the Commission A.
- In the event of combination therapy with Lithium, a follow-up of blood levels would be necessary which is anyway standard for Lithiumtherapy in Germany.

At the moment, we do not have information on the other counterindications for epilepsy, renal impairment, hepatic insufficiency,
acute intoxication, but Nick will try to speak to Prof.

the rapporteur, to find out more. In the meantime, we have learned
that Dr. Karkos will come back on September 15 and we know that a
meeting is planned on that day at the BGA to discuss the wording.
Straster suggests that we make a proposal for the wording of these
issues after having taken into account the advice of the Commission A
and Nick will work with Allan on this. I hope we can agree on this
in the coming week and that we will have a chance to present our
proposal and influence the wording that will be decided in this
September meeting.

So far so good. Let's keep our fingers crossed for another couple of weeks.

Regards,

Claude

BOUCHT CLAUDS

IVH1